התחל
ReutersReuters

Biontech And Ryvu Therapeutics To Develop And Commercialize Immuno-Modulatory Small Molecule Candidates

BNTXRVU

Biontech Se BNTX:

  • BIONTECH AND RYVU THERAPEUTICS ENTER INTO GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE IMMUNO-MODULATORY SMALL MOLECULE CANDIDATES

  • COMPANIES ENTER A MULTI-TARGET RESEARCH COLLABORATION TO DEVELOP MULTIPLE SMALL MOLECULE PROGRAMS TARGETING IMMUNE MODULATION IN CANCER AND POTENTIALLY OTHER DISEASE AREAS BASED ON TARGETS SELECTED BY BIONTECH

  • IN ADDITION TO THESE PROGRAMS, BIONTECH WILL RECEIVE A GLOBAL, EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE RYVU'S STING AGONIST PORTFOLIO AS STANDALONE SMALL MOLECULES

  • RYVU WILL RECEIVE EUR 40 MILLION FROM BIONTECH, COMPRISED OF A EUR 20 MILLION UPFRONT PAYMENT AND AN EQUITY INVESTMENT OF EUR 20 MILLION, AS WELL AS RESEARCH FUNDING

  • ADDITIONALLY, RYVU IS ELIGIBLE TO RECEIVE RESEARCH AND DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS IN ADDITION TO LOW SINGLE-DIGIT ROYALTIES

התחבר או צור חשבון בחינם לתמיד כדי לקרוא את החדשות האלה